CytomX Therapeutics Inc (NASDAQ:CTMX) has been given a consensus recommendation of “Buy” by the thirteen research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $40.17.
Several research analysts have recently commented on CTMX shares. BidaskClub lowered CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 30th. Zacks Investment Research lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 19th. Bank of America lifted their target price on CytomX Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Citigroup started coverage on CytomX Therapeutics in a research report on Friday, January 5th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Jefferies Group lifted their target price on CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th.
NASDAQ CTMX traded up $0.54 during mid-day trading on Thursday, reaching $29.68. 273,973 shares of the company’s stock traded hands, compared to its average volume of 372,551. The firm has a market cap of $1,128.99, a PE ratio of -25.59 and a beta of 0.91. CytomX Therapeutics has a 1-year low of $13.00 and a 1-year high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.43) by $0.45. The company had revenue of $27.07 million during the quarter, compared to analyst estimates of $10.70 million. CytomX Therapeutics had a negative return on equity of 71.42% and a negative net margin of 60.17%. equities analysts anticipate that CytomX Therapeutics will post -1.44 EPS for the current year.
In related news, Director Frederick W. Gluck sold 3,819 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $30.00, for a total value of $114,570.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Debanjan Ray sold 2,548 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $26.69, for a total value of $68,006.12. Following the completion of the sale, the chief financial officer now directly owns 4,741 shares in the company, valued at approximately $126,537.29. The disclosure for this sale can be found here. In the last three months, insiders sold 103,548 shares of company stock worth $3,101,686. Company insiders own 4.70% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in CTMX. New York State Common Retirement Fund lifted its holdings in shares of CytomX Therapeutics by 18.6% in the 3rd quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 5,800 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of CytomX Therapeutics by 11.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 129,182 shares of the biotechnology company’s stock worth $2,347,000 after purchasing an additional 13,405 shares during the last quarter. Macquarie Group Ltd. bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $107,000. Schroder Investment Management Group bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $489,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of CytomX Therapeutics by 47.3% in the 3rd quarter. Wells Fargo & Company MN now owns 60,739 shares of the biotechnology company’s stock worth $1,104,000 after purchasing an additional 19,506 shares during the last quarter. 78.07% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “CytomX Therapeutics Inc (CTMX) Given Consensus Rating of “Buy” by Analysts” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/19/cytomx-therapeutics-inc-ctmx-given-consensus-rating-of-buy-by-analysts-2.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.